Articles from 180 Life Sciences Corp.

PALO ALTO, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (“180” or the “Company”) is pleased to announce the appointment of Omar Jimenez as its new Chief Financial Officer, effective September 30, 2024. Mr. Jimenez, already a director of the Company, will play a key role in driving the financial strategy of the Company as it continues to grow and innovate in the pharma and biotechnology sectors.

PALO ALTO, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- PALO ALTO, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQATNF) (“180 Life Sciences” or the “Company”), today announced topline results from a clinical pharmacology study (the “Study”), that evaluated the uptake of cannabidiol (CBD) in a solid formulation which can be delivered as a pill orally. The clinical trial in humans, performed with Prof. Avi Domb of the Hebrew University, School of Pharmacy, and with Prof. Elyad Davidson, of Hadassah Hospital, compared two solid formulations of CBD with a U.S. Food and Drug Administration (FDA) approved drug for epilepsy, Epidiolex. The purpose of the Study was to compare the pharmokinetic (PK) profile of a generic approved CBD product, Epidiolex®, with two solid formulations. We believe this type of trial has yet to be examined in a clinical setting. For the Company’s trial, twelve volunteers received all three formulations in a crossover randomized trial.

PALO ALTO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQATNF) (“180 Life Sciences” or the “Company”), today announced that it received notice from the Nasdaq Listing Qualifications Panel (the “Hearings Panel”) of The Nasdaq Stock Market LLC (“Nasdaq”) that the Hearings Panel has granted the Company’s request for additional time to achieve compliance with Nasdaq’s continued listing rules and demonstrate long-term compliance with the Equity Rule (defined below). Specifically, the Hearings Panel has agreed to provide the Company until September 20, 2024 to regain compliance with the Equity Rule and to allow the continued listing of the Company’s common stock and warrants on The Nasdaq Stock Market through such date, subject to the Company’s compliance with the Equity Rule on or prior to such date.

PALO ALTO, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQATNF) (“180 Life Sciences” or the “Company”), today announced that it received notice from the Nasdaq Listing Qualifications Panel (the “Hearings Panel”) of The Nasdaq Stock Market LLC (“Nasdaq”) that the Hearings Panel has determined to grant the Company’s request to continue its listing on The Nasdaq Stock Market, subject to the Company meeting certain conditions, including filing on or before July 31, 2024, a public disclosure describing the transactions undertaken by the Company to achieve compliance with Nasdaq’s continued listing rules and demonstrate long-term compliance with the Equity Rule (defined below) and providing an indication of its equity following those transactions.

PALO ALTO, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQATNF) (“180 Life Sciences” or the “Company”), today announced that the Company received a letter on March 13, 2024 from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company has regained full compliance with the minimum bid price for continued listing on the Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2) (“Minimum Bid Price Requirement”).

PALO ALTO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQATNF) (“180 Life Sciences” or the “Company”), today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-19 (the “Reverse Stock Split”). The Reverse Stock Split is expected to become effective on February 28, 2024 at 12:01 p.m. Eastern Time (the “Effective Time”), with shares expected to begin trading on the Nasdaq Capital Market, on a split-adjusted, at market open on February 28, 2024. In connection with the Reverse Stock Split, every 19 shares of the Company’s common stock issued and outstanding as of the Effective Time will be automatically converted into one share of the Company’s common stock. No change will be made to the trading symbol for the Company’s shares of common stock or public warrants, “ATNF” and “ATNFW”, respectively, in connection with the reverse split.

PALO ALTO, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQATNF) (“180 Life Sciences” or the “Company”), today announced it has engaged A.G.P./Alliance Global Partners as financial advisor to explore and evaluate strategic alternatives to enhance shareholder value.

PALO ALTO, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQATNF) (“180 Life Sciences” or the “Company”), today announced that its Board of Directors has initiated a process to evaluate potential strategic alternatives with the intent to unlock and maximize shareholder value. In consultation with financial and legal advisors, the Company intends to consider a broad range of strategic, operational and financial alternatives, and is exploring a full range of options.

PALO ALTO, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the “Company”), a clinical-stage biotechnology company, today announced the closing of its previously announced public offering of 4,615,385 shares of the Company’s common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 4,615,385 shares of common stock at a purchase price per share (and accompanying warrant) of $0.65. The warrants are immediately exercisable at an exercise price of $0.65 per share and will expire October 10, 2028. The gross proceeds from the offering are approximately $3 million, before deducting the placement agent’s fees and other offering expenses.

PALO ALTO, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the “Company”), a clinical-stage biotechnology company, today announced the pricing of a public offering of 4,615,385 shares of the Company’s common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 4,615,385 shares of common stock at a purchase price per share (and accompanying warrant) of $0.65. The warrants will be immediately exercisable at an exercise price of $0.65 per share and will expire October 10, 2028. The gross proceeds from the offering are expected to be approximately $3 million, before deducting the placement agent’s fees and other offering expenses.

PALO ALTO, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQATNF) (“180 Life Sciences” or the “Company”), today announced that an agreement has been reached with Prof. Avi Domb of the Hebrew University, School of Pharmacy, and with Prof. Elyad Davidson, of Hadassah Hospital, to perform a clinical pharmacology (“Pharmacokinetic” or “PK”) study of the uptake of cannabidiol (CBD) in a formulation which can be delivered as a pill orally. The PK study will seek to determine how much CBD is taken up into the blood of volunteers.

PALO ALTO, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain announces that it has submitted a request to the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) for a follow up scientific advice meeting where the Company will seek guidance on a plan to obtain Conditional Marketing Authorization (CMA) for the use of adalimumab in the treatment of early stage Dupuytren’s disease.

PALO ALTO, Calif., July 31, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQATNF) (“180LS” or the “Company”), today announced the filing of a provisional patent describing the novel combination of CBD, or an analog thereof, with glucagon related peptide-1 (GLP-1) agonists to address the problem of obesity and weight management. Co-administration of Cannabidiol (CBD), a known appetite suppressant and antiemetic, might be expected both to limit the deleterious side effects and lower the effective dosage of the GLP-1 agonists.

PALO ALTO, Calif., April 10, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the “Company”), a clinical-stage biotechnology company, today announced the closing of its previously announced issuance and sale of 1,570,680 shares of the Company’s common stock (or common stock equivalents in lieu thereof) in a registered direct offering and warrants to purchase up to 1,570,680 shares of common stock at a purchase price per share (and accompanying warrant) of $1.91 in a concurrent private placement (together with the registered direct offering, the “offering”), each priced at-the-market under Nasdaq rules. The private placement warrants have an exercise price of $1.78 per share, are immediately exercisable and will expire five and one-half years from the date of issuance.

Priced At-The-Market Under Nasdaq Rules

PALO ALTO, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQATNF) (“180 Life Sciences” or the “Company”), today announced that Professor Jagdeep Nanchahal has been selected to present at the Gordon Research Conference on “Physiological and Disease Relevance and Underlying Molecular Properties of Collagens”, at Colby-Sawyer College, New London, New Hampshire, from July 9 – 14, 2023.

PALO ALTO, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQATNF) (“180 Life Sciences” or the “Company”), today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a Notice of Allowance for United States (US) patent application number 17/721,106 entitled “Method of Treating Dupuytren’s disease Using a Pre-filled Syringe”, which includes claims relating to the use of a citrate-free formulation of 40mg in 0.4mL of adalimumab to be injected into nodules of early-stage Dupuytren’s disease every 3 months over a period of 12 months using a syringe with a 25 gauge needle. This reflects the dosage and method used in the RIDD trial led by Professor Nanchahal and his colleagues at the University of Oxford, the results of which were published in The Lancet Rheumatology.

PALO ALTO, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQATNF) (“180 Life Sciences” or the “Company”), today announced closure to recruitment of men and women across England with early stage Frozen shoulder for a trial to determine the feasibility of conducting a large randomized controlled trial to assess whether an intra-articular injection of anti-TNF (Adalimumab) can reduce pain and improve function in people with pain predominant early-stage frozen shoulder, which was called the Anti-Freaze-F trial. The Anti-Freaze-F trial is being run by the University of Oxford and originally sought to recruit 84 participants.

PALO ALTO, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQATNF) (“180 Life Sciences” or the “Company”), today announced the publication of a review entitled ‘Treatments for early stage Dupuytren’s disease: an evidence-based approach’ in The Journal of Hand Surgery (European Volume).

PALO ALTO, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQATNF) (“180 Life Sciences” or the “Company”), today announced that the Company has engaged Kinexum, a strategic advisory firm, to support the Company in submitting a Marketing Authorisation Application (MAA) for adalimumab to treat progressive early-stage Dupuytren’s disease. The MAA will be submitted to the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA or Agency). As part of the application, the Company expects to request a Conditional Marketing Authorisation (CMA), which assures the Agency that long term outcome data will be forthcoming. Including the costs associated with the Kinexum agreement, the Company anticipates that it will spend, in aggregate, approximately $900,000 to $1,000,000 in the next three quarters for activities associated with the MHRA filing and other regulatory preparations.

PALO ALTO, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQATNF) (“180 Life Sciences” or the “Company”), today announced that the Company received a letter on January 4, 2023 from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company has regained full compliance with the minimum bid price for continued listing on the Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2) (“Minimum Bid Price Requirement”).

PALO ALTO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQATNF) (“180 Life Sciences” or the “Company”), today announced the publication of a review entitled ‘Dupuytren’s disease: a localized and accessible human fibrotic disorder’ in the journal Trends in Molecular Medicine.

PALO ALTO, Calif., Dec. 29, 2022 (GLOBE NEWSWIRE) --

PALO ALTO, Calif., Dec. 23, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the “Company”), a clinical-stage biotechnology company, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules with a single healthcare-focused U.S. institutional investor of 1,714,286 shares of the Company’s common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 2,571,429 shares of common stock at a purchase price per share (and accompanying warrant) of $3.50. The warrants have an exercise price of $3.50 per share, are initially exercisable beginning six months following the date of issuance and expire five years from the initial exercise date.

PALO ALTO, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) --  180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the “Company”), a clinical-stage biotechnology company, today announced that it has entered into a definitive agreement with a single healthcare-focused U.S. institutional investor, for the purchase and sale of 1,714,286 shares of the Company’s common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 2,571,429 shares of common stock at a purchase price per share (and accompanying warrant) of $3.50 in a registered direct offering priced at-the-market under Nasdaq rules. The warrants will have an exercise price of $3.50 per share, will be initially exercisable beginning six months following the date of issuance and will expire five years from the initial exercise date.

PALO ALTO, Calif., Dec. 16, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQATNF) (“180 Life Sciences” or the “Company”), today announced that it will effect a one-for-20 reverse stock split (“reverse split”) of its common stock, $0.0001 par value per share (“Common Stock”), that will become effective on December 19, 2022 at 12:01 a.m. EST. The shares of the Company’s common stock are expected to begin trading on the NASDAQ Capital Market (“NASDAQ”) on a post-split basis on December 19, 2022. No change was made to the trading symbol for the Company’s shares of common stock or public warrants, “ATNF” and “ATNFW”, respectively, in connection with the reverse split.

PALO ALTO, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQATNF) (“180 Life Sciences” or the “Company”), today announced that the Company and its regulatory consultants from the US and the UK, met with the UK Medicines and Healthcare products Regulatory Agency (MHRA) scientific advice committee for the second time on October 31, 2022. The Company provided additional data to MHRA concerning the use of nodule size and hardness as surrogate markers relating to eventual finger contraction in Dupuytren’s disease, and raised a series of questions to MHRA. On November 23, 2022, the Company received formal written scientific advice regarding such matters.

PALO ALTO, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that the Company will participate in A.G.P.’s Virtual Biotech Conference to be held November 30 – December 1, 2022.

PALO ALTO, Calif., Nov. 15, 2022 (GLOBE NEWSWIRE) -- A correction has been issued for the release disseminated under the same headline on Thursday, November 15th by 180 Life Sciences Corp. An embedded link has been added to the 5th paragraph. The complete and corrected release follows.

PALO ALTO, Calif., Nov. 15, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company today announced that researchers at Oxford Population Health’s Health Economics Research Centre and the Kennedy Institute of Rheumatology have found that anti-TNF treatment (adalimumab), which is commonly used to treat conditions such as rheumatoid arthritis and psoriasis, is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.

PALO ALTO, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company, today announced that a team led by researchers at University of Oxford have been awarded a grant from the National Institute for Health and Care Research (NIHR) in the U.K. to conduct a feasibility trial to investigate whether anti-tumor necrosis factor (TNF) therapy, administered at the time of surgery, can reduce or prevent post operative delirium/cognitive deficit (“post-operative delirium”).